BIOMAT Database Logo BIOMAT Database Logo

Elevated substance P content in induced sputum from patients with asthma and patients with chronic bronchitis. 1995

M Tomaki, and M Ichinose, and M Miura, and Y Hirayama, and H Yamauchi, and N Nakajima, and K Shirato
First Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.

In experimental studies, tachykinins, especially substance P (SP), cause many of the pathophysiological features of neurogenic inflammation. It is unclear whether these peptides are involved in human airway inflammation in diseases such as asthma and chronic bronchitis. To elucidate the relation between neurogenic inflammation and airway inflammatory diseases, we examined the SP concentration in sputum after hypertonic saline inhalation challenge in patients with asthma, patients with chronic bronchitis, and normal volunteers. SP concentration was measured by radioimmunoassay. The sputum SP concentration was significantly higher in patients with asthma (mean +/- SEM, 17.7 +/- 2.4 fmol/ml; p < 0.01) and patients with chronic bronchitis (25.6 +/- 5.5 fmol/ml; p < 0.01) than in normal volunteers (1.1 +/- 0.4 fmol/ml). In patients with asthma, the SP concentration was significantly related to the eosinophil cell count in induced sputum. In all subjects, the SP concentration in induced sputum correlated with FEV1/FVC. These data suggest that neurogenic inflammation may be involved in the airway inflammatory process and subsequent airway narrowing not only in asthma but also in chronic bronchitis.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D001985 Bronchial Provocation Tests Tests involving inhalation of allergens (nebulized or in dust form), nebulized pharmacologically active solutions (e.g., histamine, methacholine), or control solutions, followed by assessment of respiratory function. These tests are used in the diagnosis of asthma. Allergen Bronchial Provocation Tests,Allergen Challenge, Endobronchial,Antigen Bronchial Provocation Tests,Bronchial Allergen Challenge,Bronchial Challenge Tests,Inhalation Provocation Tests,Provocation Tests, Bronchial,Endobronchial Challenge Tests,Allergen Challenge, Bronchial,Allergen Challenges, Bronchial,Allergen Challenges, Endobronchial,Bronchial Allergen Challenges,Bronchial Challenge Test,Bronchial Provocation Test,Challenge Test, Bronchial,Challenge Test, Endobronchial,Challenge Tests, Bronchial,Challenge Tests, Endobronchial,Challenge, Bronchial Allergen,Challenge, Endobronchial Allergen,Challenges, Bronchial Allergen,Challenges, Endobronchial Allergen,Endobronchial Allergen Challenge,Endobronchial Allergen Challenges,Endobronchial Challenge Test,Inhalation Provocation Test,Provocation Test, Bronchial,Provocation Test, Inhalation,Provocation Tests, Inhalation,Test, Bronchial Challenge,Test, Bronchial Provocation,Test, Endobronchial Challenge,Test, Inhalation Provocation,Tests, Bronchial Challenge,Tests, Bronchial Provocation,Tests, Endobronchial Challenge,Tests, Inhalation Provocation
D001991 Bronchitis Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI. Bronchitides
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004804 Eosinophils Granular leukocytes with a nucleus that usually has two lobes connected by a slender thread of chromatin, and cytoplasm containing coarse, round granules that are uniform in size and stainable by eosin. Eosinophil
D005260 Female Females
D005541 Forced Expiratory Volume Measure of the maximum amount of air that can be expelled in a given number of seconds during a FORCED VITAL CAPACITY determination . It is usually given as FEV followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity. Forced Vital Capacity, Timed,Timed Vital Capacity,Vital Capacity, Timed,FEVt,Capacities, Timed Vital,Capacity, Timed Vital,Expiratory Volume, Forced,Expiratory Volumes, Forced,Forced Expiratory Volumes,Timed Vital Capacities,Vital Capacities, Timed,Volume, Forced Expiratory,Volumes, Forced Expiratory
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M Tomaki, and M Ichinose, and M Miura, and Y Hirayama, and H Yamauchi, and N Nakajima, and K Shirato
Histamine content of sputum from patients with asthma and chronic bronchitis.
January 1982, Clinical allergy,
M Tomaki, and M Ichinose, and M Miura, and Y Hirayama, and H Yamauchi, and N Nakajima, and K Shirato
[Determination of plasma and sputum substance P content in patients with chronic obstructive pulmonary disease or asthma].
October 2005, Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA,
M Tomaki, and M Ichinose, and M Miura, and Y Hirayama, and H Yamauchi, and N Nakajima, and K Shirato
Cellular characteristics of sputum from patients with asthma and chronic bronchitis.
September 1989, Thorax,
M Tomaki, and M Ichinose, and M Miura, and Y Hirayama, and H Yamauchi, and N Nakajima, and K Shirato
[Elevated substance P content in sputum and plasma in patients with COPD and its relationship with FEV1/FVC].
March 2000, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases,
M Tomaki, and M Ichinose, and M Miura, and Y Hirayama, and H Yamauchi, and N Nakajima, and K Shirato
[Eotaxin in induced sputum in patients with asthma and chronic bronchitis: relationship with airway inflammation].
January 2002, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases,
M Tomaki, and M Ichinose, and M Miura, and Y Hirayama, and H Yamauchi, and N Nakajima, and K Shirato
[The electrolyte content of the sputum and serum in patients with bronchial asthma and in patients with chronic bronchitis].
January 1968, Allergie und Asthma,
M Tomaki, and M Ichinose, and M Miura, and Y Hirayama, and H Yamauchi, and N Nakajima, and K Shirato
The effect of bromhexine on sputum from patients with chronic bronchitis and asthma.
January 1974, British journal of diseases of the chest,
M Tomaki, and M Ichinose, and M Miura, and Y Hirayama, and H Yamauchi, and N Nakajima, and K Shirato
Sputum eosinophilia in chronic bronchitis and asthma.
January 1978, Respiration; international review of thoracic diseases,
M Tomaki, and M Ichinose, and M Miura, and Y Hirayama, and H Yamauchi, and N Nakajima, and K Shirato
Mediators of immediate-type hypersensitivity in sputum from patients with chronic bronchitis and asthma.
September 1977, Lancet (London, England),
M Tomaki, and M Ichinose, and M Miura, and Y Hirayama, and H Yamauchi, and N Nakajima, and K Shirato
[Cytological and biochemical indices of induced sputum in patients with bronchial asthma and chronic obstructive bronchitis].
January 2002, Tsitologiia,
Copied contents to your clipboard!